Objective To Observe The Clinical Efficacy Of Fuzhengruangansuopi Prescription In The Treatment Of Hypersplenism Causing By Hepatitis B Cirrhosis

ObjectiveThe research aimed at observing the clinical efficiency of Fuzhengruangansuopi prescription which is Professor Xiong Wensheng’s experienced prescription treating hepatitis B cirrhosis in the treatment of hypersplenism caused by hepatitis B cirrhosis.MethodsThe research collected patients with hypersplenism caused by hepatitis B cirrhosis in Piwei Department in the First Affiliated hospital of Traditional Chinese Medicine University Of Guangzhou, containing outpatients and inpatients, in the past six months and put them into the observation. The patients were diveded into two groups which contained Chinese-Western Medicine Group and Western Medicine Group randomly and equally. Patients in the former group were treated by Fuzhengruangansuopi prescription and nucleotide analogue while the patients in the other group were treated by nucleotide analogue only. All the treatments lasted for 30 days. The symptoms and the results of laboratory testing which includ not only the countings of white blood cell, red blood cell and blood platelet, but also the size of spleen and the diameters of splenic vein and portal vein both before and after the treatment were recorded. The treatment effects of the two groups were compared by analyzing the data with statistical software.ResultsBoth two groups had a clinically significant improvement in symptoms after the treatments and had no significant difference between them(P>0.05). The countings of white blood cell, red blood cell and blood platelet all increaded in two groups after the treatments and the Chinese-Western Medicine Group had a significant increasing (P<0.05) on white cell while the other group did not (P >0.05). The size of spleen and the diameters of splenic vein and portal vein did not have a significant reducing after the treatments in both groups(P >0.05).Male patients were much more than female patients but there were no significant differences between the two generations on symptoms, the countings of blood cells, the size of spleen and the the diameters of splenic vein and portal vein(P>0.05).ConclusionA conclusion could be obtained that the treatment effects of the combination of Fuzhengruangansuopi prescription and nucleotide analogue on hypersplenism causing by hepatitis B cirrhosis is significantly better than nucleotide analogue only on the increasing of blood cells.